Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 150 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Pevonedistat in addition to azacitidine for Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low Blast Acute Myeloid Leukemia – first-line	Azacitidine (Vidaza; CC-486) , Pevonedistat (MLN-4924; TAK-924)	Acute myeloid leukaemia (AML) , Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS)	Haematological Cancer and Lymphomas	2020	View \| Download
Pembrolizumab with or without standard adjuvant therapy after resection for nonsmall-cell lung cancer - adjuvant	Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab inaddition to chemotherapy for persistent, recurrent or metastatic cervical cancer – first line	Pembrolizumab (Keytruda; MK-3475)	Cervical cancer	Female Reproductive Cancer	2020	View \| Download
Pembrolizumab in combination with olaparib for anti-hormone and chemotherapy failure metastatic castration-resistant prostate cancer – third line	Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Pembrolizumab in combination with ipilimumab for advanced non-small cell lung cancer	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line	Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to lenvatinib for PD-L1 positive (at least 1%) non-small-cell lung cancer – first line	Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pembrolizumab in addition to docetaxel for chemotherapy-naive metastatic castration-resistant prostate cancer – second line	Docetaxel (Taxotere; docetaxel trihydrate; docetaxel anhydrous) , Pembrolizumab (Keytruda; MK-3475)	Prostate cancer	Male Reproductive Cancer	2020	View \| Download
Pembrolizumab for renal cell carcinoma - adjuvant therapy post nephrectomy	Pembrolizumab (Keytruda; MK-3475)	Renal cell carcinoma (RCC)	Renal Cancer	2020	View \| Download
Pembrolizumab as adjuvant therapy for resected high-risk stage II melanoma	Pembrolizumab (Keytruda; MK-3475)	Melanoma	Skin Cancer	2020	View \| Download